News - Latuda


Current filters:


Popular Filters

Takeda gains first European approval for lurasidone


Japan's largest drugmaker Takeda Pharma (TYO: 4502) says it has been granted approval by Switzerland's…

Dainippon Sumitomo PharmaEuropeLatudalurasidoneNeurologicalPharmaceuticalRegulationTakeda Pharmaceuticals

Sunovion files two sNDAs for Latuda with FDA


Sunovion Pharmaceuticals, a US subsidiary of Japanese drug major Dainippon Sumitomo (TYO: 4506) has submitted…

Dainippon Sumitomo PharmaLatudaNeurologicalNorth AmericaPharmaceuticalRegulationSunovion

Dainippon Sumitomo's Latuda meets key endpoints in two Ph III trials in bipolar I depression


Japanese drugmaker Dainippon Sumitomo Pharma (4506: JP) Co., Ltd. (DSP) announced has results from two…

Dainippon Sumitomo PharmaLatudaNeurologicalPharmaceuticalResearch

Sunovion’s Latuda non-inferior to AstraZeneca’s Seroquel XR in risk relapse for schizophrenia patients


Sunovion Pharmaceuticals (SEPR: US) has announced results from a 12-month, double-blind extension study…

AstraZenecaLatudaNeurologicalPharmaceuticalResearchSeroquel XRSunovion

Company Spotlight

Eleven Biotherapeutics

Eleven Biotherapeutics

Back to top